Northern California Retina Vitreous Associates (NCRVA) is nationally recognized and active in clinical trials for the past fifteen years. We are proud to have been involved in the landmark studies that brought vision saving treatments including Lucentis (ranibizumab, Genentech), Eylea (aflibercept, Regeneron), Ozurdex (dexamethasone implant, Allergan), and photodynamic therapy (visudyne, Novartis) for retinal diseases involving age related macular degeneration (wet AMD), retinal vein occlusions, and diabetic macular edema.
The physicians at NCRVA are dedicated to bring you the most advanced surgical and medical care available. Our research team is committed to carefully selecting well-designed, safe clinical studies that offer promising and exciting new treatments for our patients. Our clinical trials are a valuable opportunity for patients to access novel treatments for retinal diseases.